EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Ann Rheum Dis 2024 doi: 10.1136/ard-2024-225531 Epub ahead of print
The 2023 EULAR recommendations provided an updated consensus on the pharmacological management of PsA with a new overarching principle and recommendation for 2023. Recent MOA safety data emphasised the importance of patient-specific benefit-risk profiling in JAKi therapy, and extra-musculoskeletal (MSK) manifestations related to PsA should be considered during drug selection.
Phase I and II of the recommendation’s algorithm were largely unchanged compared with the 2019 suggestions. Phase III was modified to emphasise consideration of non-MSK manifestations and risk assessments for JAKi use. These recommendations should be updated regularly with the arrival of new therapies and safety data.
